Rajeev Sivasankaran, PhD, vice president of neuroscience at Voyager Therapeutics, discussed preclinical data on the company’s AAV-delivered RNA interference therapy, VY-1706.
Rajeev Sivasankaran, PhD
Advertisement
vice president of neuroscience at Voyager Therapeutics
Articles by Rajeev Sivasankaran, PhD
The vice president of neuroscience at Voyager Therapeutics shared preclinical data on the company’s AAV-delivered RNA interference therapy, VY-1706.
Advertisement
Latest Updated Articles
Rajeev Sivasankaran, PhD, on Voyager’s Single-Dose AAV Strategy for Silencing Tau for Alzheimer DiseasePublished: August 6th 2025 | Updated: August 6th 2025
Advertisement
Advertisement
